Single-cell resolution
We harness the richness of single-cell multiomics data to explain complex biological processes
Artificial Intelligence
We apply AI for unbiased, innovative, sensitive, and integrative multiomics data analysis
Biomarker discovery
We deliver translatable biomarker signatures related to therapy response, diagnosis or disease severity
We ensure the success of your biomarker discovery project
Faster time-to-insights for accelerated biomarker discovery
End-to-end single-cell data generation to data insights within a few weeks
Sensitive and specific biomarker discovery
We reach high discovery success rates with our best-in-class AI algorithm, using a sensitive, specific, indication- and data- agnostic analysis approach
Fully transparent and explainable results
Our AI platform retains single-cell resolution throughout the analysis and allows scientists to explore how genes or proteins drive predictions, thereby opening the “black box”
Scailyte is a Swiss-based start-up specialized in generating actionable insights/biosignatures from multi-omics single-cell data using AI. Our AI platform, ScaiVision, combines features to integrate different datasets, is indication- and cell-type agnostic and uses data augmentation and a cluster-free approach to extract relevant information while retaining single-cell resolution. These features result in very high discovery success rates from a limited number of samples, with actionable insights for the basis of assay development.
Our Offer
For Cell & Gene Therapy companies
For Immuno-Oncology, Inflammation and Immunology companies
Partner Testimonials
Prof. Dr Michael Mueller
Leading Clinician in Women’s Health & Scientific Advisor
Pascal Koenig
Entrepreneur & Chairman of the Board of Directors
Dominique Mégret
Scailyte Board of Directors & Head Swisscom Ventures
Prof. Woong-Yang Park
Founder and CEO of Geninus
Recent News
Meet Scailyte at BioTechX
Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.
Recent News
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Recent News
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Recent News
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
Meet Scailyte at BioTechX
Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel